Cardiology

Leman Cardiovascular: Novel, Third Generation Heart Valve Shows a Major Improvement in Performance, Better Through Flow and 100% Survival in Animal Studies

Published in Lab Law Weekly, February 22nd, 2008

Leman Cardiovascular ("LCV"), a Swiss biomedical device company focused on developing the third generation of heart valve, announced that it has successfully completed animal studies to evaluate the in vivo safety, performance, healing and handling characteristics in both the aortic and mitral positions of its heart valve. Testing was carried out in compliance with ISO/FDA standards. Results showed increased performance over other products, less energy loss in blood cardiac throughput and a 100% survival rate at 90 days.

The LCV heart valve is designed to maximize blood flow and requires less work to accommodate any given cardiac output. The internal supports are placed...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Law Weekly

Source: Lab Law Weekly (2008-02-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry